



EGeen RNA Program Country Card – Georgia



Georgia Overview



- Population: 3.73 million
- Five Largest Cities: Tbilisi, Kutaisi, Batumi, Rustavi, Zugdidi
- Language: Georgian
- EU Member: No
- Govt Type: Unitary Semi-Presidential Republic
- Govt. Admin.: 9 Regions + 2 'autonomous' republics
- Health System: State insurance + fee-for-service; SMIC govt. fund

Clinical Trial Network / Comments



- HC Sites: ~ 18 hospitals, ~950 outpatient clinics; most hospitals in Tbilisi; 3.2 beds per 1000
- HC being decentralized, privatized to larger degree; reforms away from ex-Soviet model
- Investigators: ICH GCP experienced, high quality, motivated, excellent data management
- Patient access high due to desire for quality treatment; large population of naive patients
- High level of clinical trials conducted in Tbilisi and largest cities
- Very high levels of cardiovascular disease


EGeen Clinical Trial Support



- Full range of clinical trial services
- Patient recruitment, clinical monitoring, data management, biostatistics, regulatory
- Pharmacovigilance, project management, ethics review, quality assurance
- EU Qualified Person (QP) assistance to obtain EU GMP certificate for manufacturing reqs.
- Cost-effective EU / EE / non-EU importation partnerships and local IMP logistics
- Institutional relationships to proactively obtain contract approvals prior to regulatory filings as needed



Georgia – Clinical Trail Process Overview



Georgia Approval Process Highlights



- No Qualified Person (QP) required; Georgia is not an EU member state
- No Central Ethic Committee (CEC); no approval needed; saves time **NOTE**
- LEC Approval prior to submission to RA; highly unusual **NOTE**
- All major submission documents need to be in Georgian language
- CTA negotiation and signatures can run parallel with LEC approval, saving time
- No need for separate Import License submissions **NOTE**
- LEC approval serves as defacto import license for IMPs **NOTE**
- Summary: Time from QP ID to Importation of IMP estimated at **12 weeks**; fastest in CEE

Note: Summary time total is an estimated average of trial complexity